Gastrointestinal stromal tumor

New nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate

Sridhar Shankar, Eric VanSonnenberg, Jayesh Desai, Pamela J. DiPiro, Annick Van Den Abbeele, George D. Demetri

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

PURPOSE: To investigate a new pattern of tumor recurrence observed at imaging in patients with metastatic gastrointestinal stromal tumor (GIST) after initial partial reponse to imatinib mesylate. MATERIALS AND METHODS: Ninety-two patients with metastatic GIST who underwent treatment in a clinical trial with oral imatinib mesylate were followed up for 29 months. An institutional review board-approved protocol was used. The study complied with the Health Insurance Portability and Accountability Act, and written informed consent was obtained from all patients. Images of the chest, abdomen, and pelvis, acquired with computed tomography (CT), positron emission tomography (PET), and, in some cases, magnetic resonance imaging, were evaluated for treatment response and disease recurrence. Thirty-nine patients (29 men, 10 women; age range, 18-84 years; mean, 49.2 years) had recurrent disease after an initial variable period of response (range, 2-24 months; median, 14.4 months). Initial response was determined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumor, and decreased attenuation at CT. Images were evaluated for disease recurrence by two experienced radiologists who were blinded to each other's interpretation but not to clinical details. Final reading was performed by consensus. RESULTS: A nodule within a mass was seen in 21 of 39 patients (in intrahepatic tumor [n = 8], extrahepatic tumor [n = 10], or both intra- and extrahepatic tumors [n = 3]) and was the first sign of disease progression in 17 of 21 patients. Other patterns of recurrence included new site of disease (n = 7), regrowth of preexistent lesion (n = 20), and mixed (more than one) pattern (n = 9). Disease progression was verified at needle biopsy (n = 16), follow-up imaging (n = 14), and/or surgical resection (n = 9). CONCLUSION: A nodule within a mass is an important sign of recurrent GIST, but measurements of overall tumor size may not enable detection of such nodules.

Original languageEnglish (US)
Pages (from-to)892-898
Number of pages7
JournalRadiology
Volume235
Issue number3
DOIs
StatePublished - Jun 1 2005

Fingerprint

Gastrointestinal Stromal Tumors
Recurrence
Neoplasms
Disease Progression
Health Insurance Portability and Accountability Act
Research Ethics Committees
Fluorodeoxyglucose F18
Needle Biopsy
Informed Consent
Pelvis
Positron-Emission Tomography
Abdomen
Imatinib Mesylate
Reading
Thorax
Tomography
Magnetic Resonance Imaging
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Gastrointestinal stromal tumor : New nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. / Shankar, Sridhar; VanSonnenberg, Eric; Desai, Jayesh; DiPiro, Pamela J.; Van Den Abbeele, Annick; Demetri, George D.

In: Radiology, Vol. 235, No. 3, 01.06.2005, p. 892-898.

Research output: Contribution to journalArticle

Shankar, Sridhar ; VanSonnenberg, Eric ; Desai, Jayesh ; DiPiro, Pamela J. ; Van Den Abbeele, Annick ; Demetri, George D. / Gastrointestinal stromal tumor : New nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. In: Radiology. 2005 ; Vol. 235, No. 3. pp. 892-898.
@article{400ba0fd13314076bbc703e2be950c02,
title = "Gastrointestinal stromal tumor: New nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate",
abstract = "PURPOSE: To investigate a new pattern of tumor recurrence observed at imaging in patients with metastatic gastrointestinal stromal tumor (GIST) after initial partial reponse to imatinib mesylate. MATERIALS AND METHODS: Ninety-two patients with metastatic GIST who underwent treatment in a clinical trial with oral imatinib mesylate were followed up for 29 months. An institutional review board-approved protocol was used. The study complied with the Health Insurance Portability and Accountability Act, and written informed consent was obtained from all patients. Images of the chest, abdomen, and pelvis, acquired with computed tomography (CT), positron emission tomography (PET), and, in some cases, magnetic resonance imaging, were evaluated for treatment response and disease recurrence. Thirty-nine patients (29 men, 10 women; age range, 18-84 years; mean, 49.2 years) had recurrent disease after an initial variable period of response (range, 2-24 months; median, 14.4 months). Initial response was determined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumor, and decreased attenuation at CT. Images were evaluated for disease recurrence by two experienced radiologists who were blinded to each other's interpretation but not to clinical details. Final reading was performed by consensus. RESULTS: A nodule within a mass was seen in 21 of 39 patients (in intrahepatic tumor [n = 8], extrahepatic tumor [n = 10], or both intra- and extrahepatic tumors [n = 3]) and was the first sign of disease progression in 17 of 21 patients. Other patterns of recurrence included new site of disease (n = 7), regrowth of preexistent lesion (n = 20), and mixed (more than one) pattern (n = 9). Disease progression was verified at needle biopsy (n = 16), follow-up imaging (n = 14), and/or surgical resection (n = 9). CONCLUSION: A nodule within a mass is an important sign of recurrent GIST, but measurements of overall tumor size may not enable detection of such nodules.",
author = "Sridhar Shankar and Eric VanSonnenberg and Jayesh Desai and DiPiro, {Pamela J.} and {Van Den Abbeele}, Annick and Demetri, {George D.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1148/radiol.2353040332",
language = "English (US)",
volume = "235",
pages = "892--898",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Gastrointestinal stromal tumor

T2 - New nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate

AU - Shankar, Sridhar

AU - VanSonnenberg, Eric

AU - Desai, Jayesh

AU - DiPiro, Pamela J.

AU - Van Den Abbeele, Annick

AU - Demetri, George D.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - PURPOSE: To investigate a new pattern of tumor recurrence observed at imaging in patients with metastatic gastrointestinal stromal tumor (GIST) after initial partial reponse to imatinib mesylate. MATERIALS AND METHODS: Ninety-two patients with metastatic GIST who underwent treatment in a clinical trial with oral imatinib mesylate were followed up for 29 months. An institutional review board-approved protocol was used. The study complied with the Health Insurance Portability and Accountability Act, and written informed consent was obtained from all patients. Images of the chest, abdomen, and pelvis, acquired with computed tomography (CT), positron emission tomography (PET), and, in some cases, magnetic resonance imaging, were evaluated for treatment response and disease recurrence. Thirty-nine patients (29 men, 10 women; age range, 18-84 years; mean, 49.2 years) had recurrent disease after an initial variable period of response (range, 2-24 months; median, 14.4 months). Initial response was determined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumor, and decreased attenuation at CT. Images were evaluated for disease recurrence by two experienced radiologists who were blinded to each other's interpretation but not to clinical details. Final reading was performed by consensus. RESULTS: A nodule within a mass was seen in 21 of 39 patients (in intrahepatic tumor [n = 8], extrahepatic tumor [n = 10], or both intra- and extrahepatic tumors [n = 3]) and was the first sign of disease progression in 17 of 21 patients. Other patterns of recurrence included new site of disease (n = 7), regrowth of preexistent lesion (n = 20), and mixed (more than one) pattern (n = 9). Disease progression was verified at needle biopsy (n = 16), follow-up imaging (n = 14), and/or surgical resection (n = 9). CONCLUSION: A nodule within a mass is an important sign of recurrent GIST, but measurements of overall tumor size may not enable detection of such nodules.

AB - PURPOSE: To investigate a new pattern of tumor recurrence observed at imaging in patients with metastatic gastrointestinal stromal tumor (GIST) after initial partial reponse to imatinib mesylate. MATERIALS AND METHODS: Ninety-two patients with metastatic GIST who underwent treatment in a clinical trial with oral imatinib mesylate were followed up for 29 months. An institutional review board-approved protocol was used. The study complied with the Health Insurance Portability and Accountability Act, and written informed consent was obtained from all patients. Images of the chest, abdomen, and pelvis, acquired with computed tomography (CT), positron emission tomography (PET), and, in some cases, magnetic resonance imaging, were evaluated for treatment response and disease recurrence. Thirty-nine patients (29 men, 10 women; age range, 18-84 years; mean, 49.2 years) had recurrent disease after an initial variable period of response (range, 2-24 months; median, 14.4 months). Initial response was determined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumor, and decreased attenuation at CT. Images were evaluated for disease recurrence by two experienced radiologists who were blinded to each other's interpretation but not to clinical details. Final reading was performed by consensus. RESULTS: A nodule within a mass was seen in 21 of 39 patients (in intrahepatic tumor [n = 8], extrahepatic tumor [n = 10], or both intra- and extrahepatic tumors [n = 3]) and was the first sign of disease progression in 17 of 21 patients. Other patterns of recurrence included new site of disease (n = 7), regrowth of preexistent lesion (n = 20), and mixed (more than one) pattern (n = 9). Disease progression was verified at needle biopsy (n = 16), follow-up imaging (n = 14), and/or surgical resection (n = 9). CONCLUSION: A nodule within a mass is an important sign of recurrent GIST, but measurements of overall tumor size may not enable detection of such nodules.

UR - http://www.scopus.com/inward/record.url?scp=18844457915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844457915&partnerID=8YFLogxK

U2 - 10.1148/radiol.2353040332

DO - 10.1148/radiol.2353040332

M3 - Article

VL - 235

SP - 892

EP - 898

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -